Clinical Trials
Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill combination that delivers powerful and consistent blood pressure reductions
Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for...
IT & Data Management
McKesson Releases New Reporting Solution for EnterpriseRx
McKesson Pharmacy Systems LLC (MPS), a software division of McKesson Corporation, announced the launch of EnterpriseRx™ Reports Director at the 2010 National Association of...
IT & Data Management
CRM Software Provider Partners With Eastern European Pharma Services Company
StayinFront, Inc., a leading global provider of enterprise-wide customer relationship management (CRM) software, mobile sales force effectiveness and on-demand CRM solutions, announced today the...
Research Insight
Novartis Phase III study of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors showing potential benefit
A Novartis Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR® (octreotide acetate for injectable suspension) extended median progression-free survival (PFS),...
Research Insight
Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients
Boehringer Ingelheim announced today promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35 th European...
News
AstraZeneca and PoZEN received approval for VIMOVO in Europe
AstraZeneca and POZEN Inc. today announced that VIMOVO (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets has cleared an important regulatory milestone by receiving positive...
Techno Trends
InnerCap Technologies offers Combinaton Capsule Technology
InnerCap Technologies, Inc., a drug delivery company, offers an advanced patent pending multi phased, multi compartmentalized capsular based delivery system. The system can be...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
